Hurdles and delays in access to anti-cancer drugs in Europe

被引：18

作者：

Ades, F. ^{[1
]}

Zardavas, D. ^{[1
]}

Senterre, C. ^{[2
]}

de Azambuja, E. ^{[1
]}

Eniu, A. ^{[3
]}

Popescu, R. ^{[4
]}

Piccart, M. ^{[1
]}

Parent, F. ^{[5
]}

机构：

[1] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium

[2] Univ Libre Bruxelles, Sch Publ Hlth, Res Ctr Epidemiol Biostat & Clin Res, B-1050 Brussels, Belgium

[3] Canc Inst Ion Chiricuta, Dept Breast Tumours, RO-400015 Cluj Napoca, Romania

[4] Hirslanden Clin Aarau, Dept Med Oncol, CH-5001 Aarau, Switzerland

[5] Univ Libre Bruxelles, Sch Publ Hlth, Res Ctr Social Approaches Hlth, B-1050 Brussels, Belgium

来源：

ECANCERMEDICALSCIENCE | 2014年 / 8卷

关键词：

drug uptake; European Medicines Agency (EMA); European Union; marketing authorization; pricing and reimbursement; prescription and compliance;

D O I：

10.3332/ecancer.2014.482

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Demographic changes in the world population will cause a significant increase in the number of new cases of cancer. To handle this challenge, societies will need to adapt how they approach cancer prevention and treatment, with changes to the development and uptake of innovative anticancer drugs playing an important role. However, there are obstacles to implementing innovative drugs in clinical practice. Prior to being incorporated into daily practice, the drug must obtain regulatory and reimbursement approval, succeed in changing the prescription habits of physicians, and ultimately gain the compliance of individual patients. Developing an anticancer drug and bringing it into clinical practice is, therefore, a lengthy and complex process involving multiple partners in several areas. To optimize patient treatment and increase the likelihood of implementing health innovation, it is essential to have an overview of the full process. This review aims to describe the process and discuss the hurdles arising at each step.

引用

页数：10

共 27 条

[1]

THE DRUG LAG ISSUE - THE DEBATE SEEN FROM AN INTERNATIONAL PERSPECTIVE [J].

ANDERSSON, F .

INTERNATIONAL JOURNAL OF HEALTH SERVICES, 1992, 22 (01) :53-72

[2]

[Anonymous], ANN ONCOL, V18, piii49

[3]

Adherence to endocrine therapy for breast cancer [J].

Chlebowski, Rowan T. ;

Geller, Michelle L. .

ONCOLOGY, 2006, 71 (1-2) :1-9

[4]

Christofides S, 2007, IFMBE PROC, V14, P3722

[5]

Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions A Comparison of Britain, Australia, and Canada [J].

Clement, Fiona M. ;

Harris, Anthony ;

Li, Jing Jing ;

Yong, Karen ;

Lee, Karen M. ;

Manns, Braden J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (13) :1437-1443

[6]

The social value of a QALY: raising the bar or barring the raise? [J].

Donaldson, Cam ;

Baker, Rachel ;

Mason, Helen ;

Jones-Lee, Michael ;

Lancsar, Emily ;

Wildman, John ;

Bateman, Ian ;

Loomes, Graham ;

Robinson, Angela ;

Sugden, Robert ;

Pinto Prades, Jose Luis ;

Ryan, Mandy ;

Shackley, Phil ;

Smith, Richard .

BMC HEALTH SERVICES RESEARCH, 2011, 11

[7]

Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval [J].

Eichler, H-G ;

Oye, K. ;

Baird, L. G. ;

Abadie, E. ;

Brown, J. ;

Drum, C. L. ;

Ferguson, J. ;

Garner, S. ;

Honig, P. ;

Hukkelhoven, M. ;

Limn, J. C. W. ;

Lim, R. ;

Lumpkin, M. M. ;

Neil, G. ;

O'Rourke, B. ;

Pezalla, E. ;

Shoda, D. ;

Seyfert-Margolis, V. ;

Sigal, E. V. ;

Sobotka, J. ;

Tan, D. ;

Unger, T. F. ;

Hirsch, G. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (03) :426-437

[8]

Approval probabilities and regulatory review patterns for anticancer drugs in the European Union [J].

Hartmann, Markus ;

Mayer-Nicolai, Christine ;

Pfaff, Otmar .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 87 (02) :112-121

[9]

Medical Bankruptcy in the United States, 2007: Results of a National Study [J].

Himmelstein, David U. ;

Thorne, Deborah ;

Warren, Elizabeth ;

Woolhandler, Steffie .

AMERICAN JOURNAL OF MEDICINE, 2009, 122 (08) :741-746

[10]

Market access for cancer drugs and the role of health economics [J].

Jonsson, B. ;

Wilking, N. .

ANNALS OF ONCOLOGY, 2007, 18 :55-66

← 1 2 3 →